Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890077 | 0.82 | AURKA (0.47) | HSD17B10KDM4ELMNAHDAC6SMN1; SMN2 | |
| SCHEMBL10141176 | 0.82 | SMN1; SMN2 (0.59) | HSD17B10HDAC6SMN1; SMN2SCN10AALDH1A1 | |
| SCHEMBL12980804 | 0.81 | HSD17B10 (0.40) | HSD17B10KDM4ELMNAHDAC6SMN1; SMN2 | |
| SCHEMBL22962270 | 0.81 | HSD17B10 (0.40) | HSD17B10KDM4ELMNAHDAC6SMN1; SMN2 | |
| SCHEMBL21499437 | 0.81 | HSD17B10 (0.40) | HSD17B10KDM4ELMNAHDAC6SMN1; SMN2 | |
| SCHEMBL23675597 | 0.81 | HDAC6 (0.39) | HSD17B10HDAC6SMN1; SMN2SCN10AHPGD | |
| SCHEMBL12980119 | 0.81 | HDAC6 (0.39) | HSD17B10HDAC6SMN1; SMN2SCN10AHPGD | |
| SCHEMBL10141045 | 0.78 | SCN10A (0.40) | HSD17B10KDM4ELMNASMN1; SMN2SCN10A | |
| SCHEMBL12232009 | 0.78 | HSD17B10 (0.38) | HSD17B10KDM4ELMNAHDAC6SMN1; SMN2 | |
| SCHEMBL13122856 | 0.78 | HTT (0.44) | HSD17B10HDAC6SMN1; SMN2SCN10AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | ATLASMEDX, INC. | 2022-12-22 | — | — | US | disclosed |
| US-9802949-B2 | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9394279-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100317568-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20100317568-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HSD17B10 2002/4885KDM4E 2318/4885LMNA 3118/4885 |
| US-20220402894-A1 | Phthalazine Derivatives as Inhibitors of PARP1, PARP2, and/or Tubulin Useful for the Treatment of Cancer | PARP2, PARP12, PARP1 | HSD17B10 1530/4885KDM4E 2587/4885LMNA 1010/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | HSD17B10 1287/4885KDM4E 4095/4885LMNA 1249/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885KDM4E 1193/4885LMNA 2800/4885 |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885 |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885KDM4E 1193/4885LMNA 2800/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | HSD17B10 1268/4885KDM4E 4219/4885LMNA 2015/4885 |
| US-20110008288-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | HSD17B10 581/4885KDM4E 1193/4885LMNA 2800/4885 |
| US-20110064698-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | HSD17B10 643/4885KDM4E 1139/4885LMNA 2791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.